Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 4
Submit an article Journal homepage
454
Views
5
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial

Zheng SongDepartment of Lymphoma, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;
,
Huaqing WangDepartment of Oncology, Tianjin Union Medical Center, Tianjin, ChinaCorrespondence[email protected]
,
Huilai ZhangDepartment of Lymphoma, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;
,
Kuo ZhaoDepartment of Lymphoma, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;
,
Man ZhangDepartment of Lymphoma, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;
&
Fang YangDepartment of Lymphoma, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;
Pages 816-821 | Received 17 May 2016, Accepted 09 Jul 2016, Published online: 22 Aug 2016

References

  • Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer. 1994;2:286–292.
  • de Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–1061.
  • Passik SD, Kirsh KL, Rosenfeld B, et al. The changeable nature of patients’ fears regarding chemotherapy: implications for palliative care. J Pain Symptom Manage. 2002;21:113–120.
  • Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
  • National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology [Internet]. Antiemesis, Version 1. 2014 [cited 2014 Dec 18]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.
  • Warr D. Management of highly emetogenicchemotherapy. Curr Opin Oncol. 2012;24:371–375.
  • Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma. 2006;7:S7–S13.
  • MASCC/ESMO Antiemetic Guideline 2013 [Internet]. [cited 2014 Dec 18]. Available from: http://www.mascc.org/assets/documents/mascc_guidelines_english_2013.
  • Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–4119.
  • Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.
  • Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.
  • Hu Z, Cheng Y, Zhang H, et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dosecisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer. 2014;22:979–987.
  • Health UDo, Services H. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2013.
  • Martin AR, Pearson JD, Cai B, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the functional living index-emesis (FLIE) with 5-day recall. Support Care Cancer. 2003;11:522–527.
  • McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17–24.
  • Maie K, Okoshi Y, Takaiwa N, et al. Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP. Ann Oncol. 2014;25:298–299.
  • Olver IN. Antiemetic study methodology: recommendations for future studies. Oncology. 1996;53:96–101.
  • Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad rangeof moderately emetogenic chemotherapies and tumortypes: a randomized, double-blind study. Support Care Cancer. 2010;18:423–431.
  • Yeo W, Mo FK, Suen JJ, et al. A randomized study of aprepitant, ondnsetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenicchemotherapy. Breast Cancer Res Treat. 2009;113:529–535.
  • Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009;17:589–594.
  • Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer. 2012;20:653–656.
  • Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.